Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory inva… Read more
Scynexis Inc (SCYX) - Total Assets
Latest total assets as of December 2025: $59.03 Million USD
Based on the latest financial reports, Scynexis Inc (SCYX) holds total assets worth $59.03 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Scynexis Inc - Total Assets Trend (2012–2025)
This chart illustrates how Scynexis Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Scynexis Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Scynexis Inc's total assets of $59.03 Million consist of 68.4% current assets and 31.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 36.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Scynexis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scynexis Inc's current assets represent 68.4% of total assets in 2025, an increase from 43.1% in 2012.
- Cash Position: Cash and equivalents constituted 36.0% of total assets in 2025, up from 19.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Scynexis Inc Competitors by Total Assets
Key competitors of Scynexis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Scynexis Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Scynexis Inc generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Scynexis Inc is currently not profitable relative to its asset base.
Scynexis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.04 | 3.00 | 3.83 |
| Quick Ratio | 7.04 | 3.00 | 3.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $34.64 Million | $ 48.08 Million | $ 70.44 Million |
Scynexis Inc - Advanced Valuation Insights
This section examines the relationship between Scynexis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | -34.9% |
| Total Assets | $59.03 Million |
| Market Capitalization | $32.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scynexis Inc's assets below their book value (0.55 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scynexis Inc's assets decreased by 34.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scynexis Inc (2012–2025)
The table below shows the annual total assets of Scynexis Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $59.03 Million | -34.88% |
| 2024-12-31 | $90.64 Million | -29.41% |
| 2023-12-31 | $128.41 Million | +46.24% |
| 2022-12-31 | $87.81 Million | -26.73% |
| 2021-12-31 | $119.84 Million | +16.87% |
| 2020-12-31 | $102.54 Million | +79.41% |
| 2019-12-31 | $57.15 Million | +7.49% |
| 2018-12-31 | $53.17 Million | +15.97% |
| 2017-12-31 | $45.85 Million | -23.32% |
| 2016-12-31 | $59.79 Million | +21.35% |
| 2015-12-31 | $49.27 Million | +24.20% |
| 2014-12-31 | $39.67 Million | +218.93% |
| 2013-12-31 | $12.44 Million | +2.65% |
| 2012-12-31 | $12.12 Million | -- |